If you’re unfamiliar with Scott Rocklage, Ph.D., he is the managing partner of 5 AM Ventures, a California-based venture capital firm. Although the business name may sound peculiar, it is a denotation of the firm’s preference for backing early-stage life science companies. Founded in 2002, 5 AM Ventures prides themselves on being a specialty venture capital firm, with the majority of their business portfolio consisting of life science companies. If you haven’t heard of term life science companies, it is abroad term used to describe a variety of companies operating in the Bio-pharmaceutical, biomedical technology, and biomedical device fields. In addition, 5 AM Ventures works with drug development companies, specifically those that develop anti-infectives and drugs aimed at treating diabetes, cancer, and metabolic diseases.
Prior to joining 5 AM Ventures, Dr. Rocklage spent the better part of two decades working in the healthcare management sector, where he exemplified leadership skills that ultimately led to him successfully submitting six drugs to clinical trials, and receiving FDA approval on three new drug applications:
Cubicin- an antibiotic prescribed to treat serious bacterial infections
Gadodiamide- used in MRI procedures to assist in the visualization of blood vessels
Teslascan- a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging of the liver.
Dr. Scott Rocklage is a University of California, Berkley alumnus, who earned a Bachelor of Science degree in Chemistry, before going on to study at MIT (Massachusetts Institute of Technology), where he earned a Ph.D. in Chemistry. In the early 90s, Dr. Rocklage spent several years with Nycomed Salutar, a Norwegian pharmaceutical company; from 1990 to 1992, he served as the President and CEO of Nycomed Salutar, and later, CEO, President, and Chairman of Nycomed Interventional, Inc, before leaving in 1994 to pursue a new career opportunity with Cubist Pharmaceuticals. In his role at Cubist Pharmaceuticals, Dr. Rocklage served as the company’s President and Founding Chief Executive Officer, until 2003.
In addition to his various C-level positions, Dr. Rocklage has held a number of research and development roles with Catalytica Pharmaceuticals and has served as Chairman of the Board for Cidara Therapeutics, a clinical-stage biotechnology company. Needless to say, Dr. Scott Rocklage is well suited for his role as managing partner of 5 AM Ventures; his pharmaceutical background along with his education makes him a tremendous asset, as 5 AM Ventures continues to back early-stage life science companies.
Connect with Dr. Scott Rocklage on LinkedIn.